SCHEMBL2906246

SCHEMBL2906246

COc1ccc(C(=O)Nc2c(C)c(C)c3c(c2C)C(c2ccccc2)C(C)(C)O3)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
GAA P10253 1/20 0.44
F10 P00742 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
NPC1 O15118 5/20 0.43
RAB9A P51151 5/20 0.43
TP53 P04637 3/20 0.42
KCNK9 Q9NPC2 1/20 0.42
ALDH1A1 P00352 4/20 0.42
ADORA3 P0DMS8 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2913757 0.92 RAB9A (0.47) MAPTGAAF10NPC1RAB9A
SCHEMBL27597976 0.90 MAPT (0.37) MAPTGAANPC1RAB9ATP53
SCHEMBL2905508 0.90 LMNA (0.44) MAPTGAANPC1RAB9ATP53
SCHEMBL2913347 0.88 RAB9A (0.42) MAPTGAAF10L3MBTL1NPC1
SCHEMBL2911504 0.88 KDM4E (0.42) MAPTNPC1RAB9ATP53KCNK9
SCHEMBL2947678 0.82 KDM4E (0.39) MAPTNPC1RAB9ATP53ALDH1A1
SCHEMBL2911427 0.82 LMNA (0.40) MAPTGAANPC1RAB9ATP53
SCHEMBL2912943 0.79 PKM (0.49) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2909184 0.79 RAB9A (0.41) MAPTGAAL3MBTL1NPC1RAB9A
SCHEMBL2910924 0.79 KDM1A (0.40) MAPTGAAL3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1481679-B1 ANTIDEPRESSANT TAKEDA PHARMACEUTICAL (JP) 2010-08-25 EP disclosed
US-7750037-B2 Antidepressant TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-06 US disclosed
EP-1323716-B1 PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS TAKEDA PHARMACEUTICAL (JP) 2009-01-14 EP disclosed
US-20090012081-A1 Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) 2009-01-08 US disclosed
US-7456162-B2 Benzofuran derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-25 US disclosed
US-20060241168-A1 Antidepressant OHKAWA SHIGENORI 2006-10-26 US disclosed
US-7101867-B2 Benzofuran derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-09-05 US disclosed
US-20050187238-A1 Benzofuran derivatives, their production and use OHKAWA SHIGENORI (JP) 2005-08-25 US disclosed
US-20050148650-A1 Antidepressant TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-07-07 US disclosed
EP-1481679-A1 ANTIDEPRESSANT Takeda Chemical Industries, Ltd. (JP) 2004-12-01 EP disclosed
EP-1136477-B1 BENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-03-10 EP disclosed
US-20040034049-A1 Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-19 US disclosed
EP-1323716-A1 PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS Takeda Chemical Industries, Ltd. (JP) 2003-07-02 EP disclosed
US-6479536-B1 Benzofuran derivatives, process for the preparation of the same and uses thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-11-12 US disclosed
US-20020160996-A1 Benzofuran derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2002-10-31 US disclosed
EP-1136477-A1 BENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148650-A1 Antidepressant AKT1S1, AKT1, AKT2 MAPT 3659/4885GAA 4232/4885F10 2229/4885
US-20060241168-A1 Antidepressant AKT1S1, AKT1, AKT2 MAPT 3659/4885GAA 4232/4885F10 2229/4885
US-20090012081-A1 Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells NES, MKI67, CCNO MAPT 4127/4885GAA 3734/4885F10 2071/4885
US-20050187238-A1 Benzofuran derivatives, their production and use WDR1, WDR82, CBR1 MAPT 1426/4885GAA 2497/4885F10 1877/4885
US-20040034049-A1 Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells NES, HAT1, PROX1 MAPT 4443/4885GAA 3770/4885F10 3192/4885
US-20020160996-A1 Benzofuran derivatives, their production and use PARK7, WDR1, WHR1 MAPT 813/4885GAA 1706/4885F10 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.